Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years

Diamant Thaçi; Stefano Piaserico; Kristian Gaarn Du Jardin; Richard B. Warren

doi:10.1111/jdv.18783

Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years

Diamant Thaçi^*, Stefano Piaserico, Kristian Gaarn Du Jardin, Richard B. Warren

^*Korrespondierende/r Autor/-in für diese Arbeit

Institut für Entzündungsmedizin

1 Zitat (Scopus)

Originalsprache	Englisch
Zeitschrift	Journal of the European Academy of Dermatology and Venereology
Jahrgang	37
Ausgabenummer	4
Seiten (von - bis)	e501-e504
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.18783
Publikationsstatus	Veröffentlicht - 04.2023

Fördermittel

We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. Richard B. Warren is supported by the Manchester NIHR Biomedical Research Centre.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
Zentren: Center for Research on Inflammation of the Skin (CRIS)

DFG-Fachsystematik

2.22-19 Dermatologie

Dokumente

10.1111/jdv.18783

Weitere Links

Link to publication in Scopus

Zitieren

@article{2ea5711d4ec34d91a522a33dc9dc0541,

title = "Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years",

author = "Diamant Tha{\c c}i and Stefano Piaserico and \{Gaarn Du Jardin\}, Kristian and Warren, \{Richard B.\}",

note = "Funding Information: We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. Richard B. Warren is supported by the Manchester NIHR Biomedical Research Centre. ",

year = "2023",

month = apr,

doi = "10.1111/jdv.18783",

language = "English",

volume = "37",

pages = "e501--e504",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc",

number = "4",

}

Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years. / Thaçi, Diamant; Piaserico, Stefano; Gaarn Du Jardin, Kristian et al.
in: Journal of the European Academy of Dermatology and Venereology, Jahrgang 37, Nr. 4, 04.2023, S. e501-e504.

Publikation: Beiträge in Fachzeitschriften › Briefe › Begutachtung

TY - JOUR

T1 - Long-term stability of PASI <3 response to tildrakizumab

T2 - Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years

AU - Thaçi, Diamant

AU - Piaserico, Stefano

AU - Gaarn Du Jardin, Kristian

AU - Warren, Richard B.

N1 - Funding Information: We would like to thank Eva Mateu, PhD of TFS HealthScience for editorial assistance and writing support. Richard B. Warren is supported by the Manchester NIHR Biomedical Research Centre.

PY - 2023/4

Y1 - 2023/4

UR - https://www.scopus.com/pages/publications/85143432553

U2 - 10.1111/jdv.18783

DO - 10.1111/jdv.18783

M3 - Letters

C2 - 36433779

AN - SCOPUS:85143432553

SN - 0926-9959

VL - 37

SP - e501-e504

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 4

ER -